221 related articles for article (PubMed ID: 32493990)
1. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer.
Youn JI; Park SM; Park S; Kim G; Lee HJ; Son J; Hong MH; Ghaderpour A; Baik B; Islam J; Choi JW; Lee EY; Kim HR; Seo SU; Paik S; Yoon HI; Jung I; Xin CF; Jin HT; Cho BC; Seong SY; Ha SJ; Kim HR
Sci Rep; 2020 Jun; 10(1):9050. PubMed ID: 32493990
[TBL] [Abstract][Full Text] [Related]
2. MDSC subtypes and CD39 expression on CD8
Koh J; Kim Y; Lee KY; Hur JY; Kim MS; Kim B; Cho HJ; Lee YC; Bae YH; Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Eur J Immunol; 2020 Nov; 50(11):1810-1819. PubMed ID: 32510574
[TBL] [Abstract][Full Text] [Related]
3. The Ratio of Peripheral Regulatory T Cells to Lox-1
Kim HR; Park SM; Seo SU; Jung I; Yoon HI; Gabrilovich DI; Cho BC; Seong SY; Ha SJ; Youn JI
Am J Respir Crit Care Med; 2019 Jan; 199(2):243-246. PubMed ID: 30339766
[No Abstract] [Full Text] [Related]
4. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils.
Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A
Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638
[TBL] [Abstract][Full Text] [Related]
5. Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients.
Juliá EP; Mandó P; Rizzo MM; Cueto GR; Tsou F; Luca R; Pupareli C; Bravo AI; Astorino W; Mordoh J; Martín C; Levy EM
Cancer Immunol Immunother; 2019 Oct; 68(10):1585-1596. PubMed ID: 31515670
[TBL] [Abstract][Full Text] [Related]
6. Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer.
Li YD; Lamano JB; Lamano JB; Quaggin-Smith J; Veliceasa D; Kaur G; Biyashev D; Unruh D; Bloch O
Cancer Immunol Immunother; 2019 Sep; 68(9):1501-1513. PubMed ID: 31489465
[TBL] [Abstract][Full Text] [Related]
7. Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer.
Barrera L; Montes-Servín E; Hernandez-Martinez JM; Orozco-Morales M; Montes-Servín E; Michel-Tello D; Morales-Flores RA; Flores-Estrada D; Arrieta O
Cancer Immunol Immunother; 2018 Sep; 67(9):1393-1406. PubMed ID: 29974189
[TBL] [Abstract][Full Text] [Related]
8. Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity.
Tumino N; Besi F; Martini S; Di Pace AL; Munari E; Quatrini L; Pelosi A; Fiore PF; Fiscon G; Paci P; Scordamaglia F; Covesnon MG; Bogina G; Mingari MC; Moretta L; Vacca P
Front Immunol; 2021; 12():803014. PubMed ID: 35116033
[TBL] [Abstract][Full Text] [Related]
9. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
Mazzaschi G; Facchinetti F; Missale G; Canetti D; Madeddu D; Zecca A; Veneziani M; Gelsomino F; Goldoni M; Buti S; Bordi P; Aversa F; Ardizzoni A; Quaini F; Tiseo M
Lung Cancer; 2019 Jan; 127():153-163. PubMed ID: 30642544
[TBL] [Abstract][Full Text] [Related]
10. Circulating CD15
Tian X; Wang T; Zheng Q; Tao Y; Dai L; Shen H
Int J Clin Pract; 2021 Aug; 75(8):e14317. PubMed ID: 33960078
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
12. PD-1
Trefny MP; Kaiser M; Stanczak MA; Herzig P; Savic S; Wiese M; Lardinois D; Läubli H; Uhlenbrock F; Zippelius A
Cancer Immunol Immunother; 2020 Aug; 69(8):1505-1517. PubMed ID: 32296919
[TBL] [Abstract][Full Text] [Related]
13. Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer.
Kaneda T; Kurata T; Yoshida T; Kibata K; Yoshioka H; Yanagimoto H; Takeda K; Yoshida T; Tsuta K
BMC Cancer; 2022 Feb; 22(1):154. PubMed ID: 35135489
[TBL] [Abstract][Full Text] [Related]
14. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
Yamauchi Y; Safi S; Blattner C; Rathinasamy A; Umansky L; Juenger S; Warth A; Eichhorn M; Muley T; Herth FJF; Dienemann H; Platten M; Beckhove P; Utikal J; Hoffmann H; Umansky V
Am J Respir Crit Care Med; 2018 Sep; 198(6):777-787. PubMed ID: 29617574
[TBL] [Abstract][Full Text] [Related]
15. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
[TBL] [Abstract][Full Text] [Related]
16. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.
Trefny MP; Rothschild SI; Uhlenbrock F; Rieder D; Kasenda B; Stanczak MA; Berner F; Kashyap AS; Kaiser M; Herzig P; Poechtrager S; Thommen DS; Geier F; Savic S; Jermann P; Alborelli I; Schaub S; Stenner F; Früh M; Trajanoski Z; Flatz L; Mertz KD; Zippelius A; Läubli H
Clin Cancer Res; 2019 May; 25(10):3026-3034. PubMed ID: 30765392
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.
Lin M; Luo H; Liang S; Chen J; Liu A; Niu L; Jiang Y
J Clin Invest; 2020 May; 130(5):2560-2569. PubMed ID: 32027620
[TBL] [Abstract][Full Text] [Related]
18. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
19. Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients.
Shimoda Y; Yoshida T; Shirasawa M; Mizuno T; Jo H; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y; Motoi N
Anticancer Res; 2021 Nov; 41(11):5739-5747. PubMed ID: 34732447
[TBL] [Abstract][Full Text] [Related]
20. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.
Cole KE; Ly QP; Hollingsworth MA; Cox JL; Padussis JC; Foster JM; Vargas LM; Talmadge JE
Cell Immunol; 2021 May; 363():104317. PubMed ID: 33714729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
